aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinica… Read more
aTyr Pharma, Inc. (ATYR) - Total Liabilities
Latest total liabilities as of December 2025: $26.88 Million USD
Based on the latest financial reports, aTyr Pharma, Inc. (ATYR) has total liabilities worth $26.88 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
aTyr Pharma, Inc. - Total Liabilities Trend (2012–2025)
This chart illustrates how aTyr Pharma, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
aTyr Pharma, Inc. Competitors by Total Liabilities
The table below lists competitors of aTyr Pharma, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ample Electronic Technology Co Ltd
TWO:4760
|
Taiwan | NT$519.41 Million |
|
Fine Foods & Pharmaceuticals N.T.M. S.p.A.
F:9S5
|
Germany | €123.98 Million |
|
NoiBai Cargo Terminal Services JSC
VN:NCT
|
Vietnam | ₫259.31 Billion |
|
Chialin Precision Industrial Co Ltd
TWO:3310
|
Taiwan | NT$4.18 Billion |
|
Full House Resorts Inc
NASDAQ:FLL
|
USA | $66.87 Million |
|
Wah Seong Corporation Bhd
KLSE:5142
|
Malaysia | RM1.44 Billion |
|
Geojit Financial Services Limited
NSE:GEOJITFSL
|
India | ₹7.69 Billion |
|
GoPro Inc
NASDAQ:GPRO
|
USA | $351.43 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down aTyr Pharma, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how aTyr Pharma, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for aTyr Pharma, Inc. (2012–2025)
The table below shows the annual total liabilities of aTyr Pharma, Inc. from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $26.88 Million | -0.46% |
| 2024-12-31 | $27.00 Million | -10.55% |
| 2023-12-31 | $30.18 Million | +23.19% |
| 2022-12-31 | $24.50 Million | +282.19% |
| 2021-12-31 | $6.41 Million | -11.47% |
| 2020-12-31 | $7.24 Million | -52.24% |
| 2019-12-31 | $15.16 Million | -20.60% |
| 2018-12-31 | $19.10 Million | -23.95% |
| 2017-12-31 | $25.11 Million | +41.68% |
| 2016-12-31 | $17.72 Million | +21.18% |
| 2015-12-31 | $14.62 Million | -86.90% |
| 2014-12-31 | $111.65 Million | +5.47% |
| 2013-12-31 | $105.87 Million | +1113.25% |
| 2012-12-31 | $8.73 Million | -- |